MiNK Therapeutics Inc. (NASDAQ: INKT) presented new clinical data on its investigational cell therapy agenT-797 at the American Thoracic Society International Conference 2026, with findings simultaneously published in Clinical Immunology Communications.

The data describes treatment of a critically ill patient with disseminated Coccidioides immitis infection, severe acute respiratory distress syndrome, and concurrent hospital-acquired Pseudomonas aeruginosa pneumonia. The patient received sequential immunotherapy combining agenT-797 with N-803, an FDA-approved IL-15 superagonist marketed as Anktiva by ImmunityBio.

Following the sequential treatment, investigators observed suppression of both fungal and bacterial pathogens, active immune cell recruitment into the lung, reduced early inflammatory signaling, and activation of tissue repair pathways. The patient's family ultimately chose comfort care due to recurrent cardiac complications related to pre-existing mitral valve disease.

"These observations are clinically and biologically important because they point to a pattern we are increasingly seeing across severe lung injury where immune failure itself may become a dominant driver of poor outcomes," said Terese Hammond, Head of Inflammatory and Pulmonary Diseases at MiNK Therapeutics.

The company recently initiated a randomized Phase 2 clinical trial evaluating agenT-797 plus standard care compared with placebo plus standard care in adults with severe acute lung injury and critical illness. The study targets patients with moderate to severe acute hypoxemic respiratory failure due to severe pneumonia who meet Global ARDS criteria and are admitted to intensive care units.

MiNK Therapeutics develops allogeneic invariant natural killer T cell therapies for immune-mediated diseases and cancer. The company's lead candidate agenT-797 is currently in clinical trials for solid tumors, graft-versus-host disease, and critical pulmonary immune failure.